EVGN News & Events

Evogene announced a scientific collaboration with Unravel Biosciences, a clinical-stage therapeutics company established to advance drugs for complex diseases through its Predictable Medicine platform. This partnership aims to accelerate the discovery and optimization of a first-in-class small-molecule therapeutic capable of restoring myelin and reversing neurological damage in demyelinating diseases. Evogene and Unravel have launched a joint effort to design and validate brain-penetrant inhibitors of a novel demyelination target discovered by Unravel's platform and create the first therapeutic designed to restore myelin and improve neurological function. By taking a function-first discovery approach, the collaboration aims at gaining unique biological insights from genetically defined demyelinating disorders. Such insights will enable translating the discovered underlying biological mechanisms that drive reversal of demyelination to a plethora of such disorders, overcoming the challenge of restoring neurological function in patients.

Evogene announces the appointment of Dr. Olga Nissan as its Vice President, VP, of Business Development, effective as of January 1, 2026. Her prior roles include CEO and Co-Founder of Protica Bio, Technology Manager at EcoPhage, Senior Scientist at BiomX.

Casterra Ag, an Israeli developer of high-yield castor seed varieties and integrated castor farming solutions, and a subsidiary of Evogene, and Fantini Italia, an Italian developer and manufacturer of agricultural harvesting equipment, announced a strategic collaboration for large-scale, commercial castor cultivation through advanced mechanization technologies. The partnership is designed to meet the rising global demand for castor oil used for the production of biofuels and bio-based industrial products, by developing comprehensive and scalable farming solutions that integrate specially bred castor varieties with cutting-edge farm machinery.

Reports Q2 revenue $2.78M vs. $4.24M last year. "Q2 2025 was a transformational quarter for EverGen as we successfully recapitalized the business, aligned our leadership with a supportive lead investor, and continued to deliver record RNG production," said Chase Edgelow, CEO of EverGen. "We're tracking well against our 100-day plan for the business, and while optimization activities will continue to impact near term revenues, these initiatives are critical to positioning EverGen for scalable growth in 2026 and beyond, reinforcing our long-term vision as Canada's leading RNG infrastructure platform."